The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study ...

Johnson & Johnson has won the support of an FDA expert panel in its bid to make Darzalex the first treatment for an early ...

"support the potential for Blenrep combinations to become standard of care" in multiple myeloma patients at or after their first relapse. The company previously teased the overall survival (OS ...

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data ...

Agency drug reviewers had questioned patient risk criteria and the efficacy endpoint used in a key trial supporting J&J's ...

New research, from COMy 2025, has found that specific senescence-associated biomarkers are significantly correlated with ...

In the two decades since a young father was diagnosed with multiple myeloma, clinical trials and advances in treating his ...

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

Positive feedback was based on Phase III AQUILA trial results, which showed a significant clinical benefit with Darzalex Faspro in patients with high-risk smoldering multiple myeloma.

Johnson & Johnson (J&J) has announced that a US Food and Drug Administration (FDA) panel of experts has recommended Darzalex ...

In the last year, there has been excitement about the use of MRD in multiple myeloma trials and new approaches to assessing ...